EUCTR2005-002765-37-DK进行中（未招募）不适用
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. - H10
Euopean Organisation of Research and Treatment of Cancer0 个研究点目标入组 1,600 人开始时间: 2006年12月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically proven Hodgkin’s lymphoma, except for the nodular lymphocyte predominant subtype (nodular paragranuloma)
- •- Supradiaphragmatic Ann Arbor clinical stage I or II, both favorable and unfavorable
- •prognostic subsets (for definition of favorable (F) and unfavorable (U), see at the end of this section)
- •- Previously untreated
- •- Age 15 through 70 years
- •- FDG-PET scan already prospectively planned after two cycles of ABVD for all patients
- •(see Appendix G).
- •- WHO performance status grades 0, 1, 2 or 3 (see Appendix B) during the whole duration of study treatment.
- •- Absence of severe cardiac, pulmonary, neurologic psychiatric or metabolic disease. Patients with unstable diabetes mellitus are excluded (to avoid uninterpretable FDG-PET scan).
- •- Adequate liver and renal function (total serum bilirubin = 2.5 x ULN, serum creatinine = 2.5 x ULN)
- •- No concomitant or previous malignancies with the exception of basal cell skin tumors, adequately treated carcinoma in situ of the cervix and any cancer that has been in complete remission for >5 years
- •- No known HIV infection
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. - H10Hodgkin’s lymphomaMedDRA version: 8.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseEUCTR2005-002765-37-NLEuopean Organisation of Research and Treatment of Cancer1,600
进行中（未招募）
不适用
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. - H10Supradiaphragmatic stage I/II Hodgkin’s lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2005-002765-37-BEEuopean Organisation of Research and Treatment of Cancer1,797
进行中（未招募）
1 期
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin's lymphoma. - H10Hodgkin’s lymphomaMedDRA version: 8.1 Level: HLGT Classification code 10025319 Term: Lymphomas Hodgkin's diseaseEUCTR2005-002765-37-SKEuopean Organisation of Research and Treatment of Cancer1,950
进行中（未招募）
不适用
The H10 EORTC/GELA randomized Intergroup trial on early FDGPET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiaphragmatic stage I/II Hodgkin,s lymphomaPatients with supradiaphragmatic stage I/II Hodgkin`s lymphomaMedDRA version: 14.1Level: HLGTClassification code 10025319Term: Lymphomas Hodgkin's diseaseSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2005-002765-37-ITEORTC Lymphoma Group1,797
尚未招募
3 期
The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaption versus standard combined modality treatment in patiënts with supradiaphragmatic stage I/II Hodgkin's lymphomaNL-OMON29848European Organisation for Research in Treatment of Cancer (EORTC)500